Glenmark Pharmaceuticals Inc., USA FDA Inspection Record
Glenmark Pharmaceuticals Inc., USA is an FDA-inspected facility (FEI 3005658103) located in Elmwood Park, NJ, US. RegDataLab tracks 3 FDA inspections and 3 compliance actions at this facility.
What FDA found at this site
- Latest inspection
- Dec 5, 2016: No Action Indicated (NAI)
- Inspections on record
- 3 (1 VAI, 2 NAI)
- Last OAI inspection
- None on record
- Warning letters
- 3 listed by FDA for this FEI, latest Mar 16, 2010
- Recalls as the recalling firm
- 65, latest Oct 9, 2026
- Import refusals
- 1
Inspections and what FDA cited
| Date | Result | What FDA cited |
|---|---|---|
| Dec 5, 2016 | No Action Indicated (NAI) | No citations listed |
| Sep 9, 2011 | No Action Indicated (NAI) | No citations listed |
| Jun 29, 2010 | Voluntary Action Indicated (VAI) | Complaint Handling Procedure (21 CFR 211.198(a)) Failure to develop written procedures (21 CFR 314.80(b)) Late submission of quarterly safety reports (21 CFR 314.80(c)(2)) |
Recalls
| Date | Class | Recall | Product and reason |
|---|---|---|---|
| Oct 9, 2026 | Class II | D-0074-2027 | Abiraterone Acetate Tablets USP 500 mg, 60-count bottles, Rx only, Distributed by… Labeling: Not Elsewhere Classified |
| Sep 10, 2026 | Class II | D-0015-2027 | Clindamycin Phosphate Foam, 1%, FOR TOPICAL USE ONLY, Rx only, 100 g can, Manufactured… Defective Container: Firm received customer complaints of damaged and leaking product. |
| Jul 23, 2026 | Class II | D-0731-2026 | Azelaic Acid Gel, 15%, 50 gram tubes, For Topical Use only, Rx only, Distributed by… CGMP Deviations: Product quality complaints concerning abnormal texture or consistency (described as grainy, gritty, or sandy) were… |
| May 27, 2026 | Class II | D-0588-2026 | Alyacen 7/7/7, Norethindrone and Ethinyl Estradiol Tablets USP, 0.5mg/0.035mg… Failed Impurities/Degradation Specifications: This recall is being initiated due to out-of-specification results total impurities. |
| Dec 30, 2025 | Class II | D-0246-2026 | Ondansetron Orally Disintegrating Tablets, USP, 4mg, 30 Tablets (3 blistercards each… Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed… |
| Nov 21, 2025 | Class III | D-0199-2026 | Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP, 2.5 mg/6.25 mg, packaged as (a)… Cross Contamination with Other Products: Testing of reserve samples showed presence of traces of ezetimibe |
| Nov 18, 2025 | Class III | D-0222-2026 | Nebivolol Tablets, 20 mg, 90 Tablets, Rx Only, Manufactured by: Glenmark Pharmaceuticals… Cross Contamination with Other Products |
| Sep 17, 2025 | Class II | D-0662-2025 | Azelaic Acid Gel, 15%, 50 grams, For Topical Use Only, Rx only, Manufactured by: Glenmark… CGMP Deviations: Market complaints received for gritty texture (grainy) |
| Sep 3, 2025 | Class II | D-0021-2026 | Viorele, Desogestrel and Ethinyl Estradiol, USP, 0.15 mg/ 0.02 mg and Ethinyl Estradiol… Failed Impurities/Degradation Specifications |
| Aug 8, 2025 | Class II | D-0583-2025 | Theophylline extended-release tablets 400mg, 100-count bottle, Rx only, Manufactured by… Failed Dissolution Specifications: Failure results (above) were reported for the Dissolution (by UV) test for commercial annual stability at… |
FDA record score
100 of 100. A count of this site's adverse public FDA records, weighted by how recent each one is. A higher number means more, or more recent, records. The records below add up to 125.8; the score stops at 100.
50 records behind this number
| Record | Date | Points x age weight | Adds |
|---|---|---|---|
| Class I recall D-0604-2024, this FEI as the recalling firm | May 30, 2024 | 15 x 0.6 | 9 |
| Class II recall D-0074-2027, this FEI as the recalling firm | Oct 9, 2026 | 4 x 1 | 4 |
| Class II recall D-0015-2027, this FEI as the recalling firm | Sep 10, 2026 | 4 x 1 | 4 |
| Class II recall D-0731-2026, this FEI as the recalling firm | Jul 23, 2026 | 4 x 1 | 4 |
| Class II recall D-0588-2026, this FEI as the recalling firm | May 27, 2026 | 4 x 1 | 4 |
| Class II recall D-0246-2026, this FEI as the recalling firm | Dec 30, 2025 | 4 x 1 | 4 |
| Class II recall D-0662-2025, this FEI as the recalling firm | Sep 17, 2025 | 4 x 1 | 4 |
| Class II recall D-0021-2026, this FEI as the recalling firm | Sep 3, 2025 | 4 x 1 | 4 |
| Class II recall D-0583-2025, this FEI as the recalling firm | Aug 8, 2025 | 4 x 1 | 4 |
| Class II recall D-0577-2025, this FEI as the recalling firm | Aug 7, 2025 | 4 x 1 | 4 |
| Class II recall D-0587-2025, this FEI as the recalling firm | Aug 6, 2025 | 4 x 1 | 4 |
| Class II recall D-0452-2025, this FEI as the recalling firm | May 15, 2025 | 4 x 1 | 4 |
| Class II recall D-0314-2025, this FEI as the recalling firm | Mar 13, 2025 | 4 x 1 | 4 |
| Class II recall D-0309-2025, this FEI as the recalling firm | Mar 11, 2025 | 4 x 1 | 4 |
| Class II recall D-0448-2025, this FEI as the recalling firm | Feb 28, 2025 | 4 x 1 | 4 |
| Class II recall D-0231-2025, this FEI as the recalling firm | Jan 29, 2025 | 4 x 1 | 4 |
| Class II recall D-0215-2025, this FEI as the recalling firm | Jan 22, 2025 | 4 x 1 | 4 |
| Class II recall D-0159-2025, this FEI as the recalling firm | Dec 11, 2024 | 4 x 1 | 4 |
| Class II recall D-0093-2025, this FEI as the recalling firm | Nov 1, 2024 | 4 x 0.6 | 2.4 |
| Class II recall D-0006-2025, this FEI as the recalling firm | Sep 24, 2024 | 4 x 0.6 | 2.4 |
| Class II recall D-0660-2024, this FEI as the recalling firm | Aug 30, 2024 | 4 x 0.6 | 2.4 |
| Class II recall D-0643-2024, this FEI as the recalling firm | Jul 31, 2024 | 4 x 0.6 | 2.4 |
| Class II recall D-0621-2024, this FEI as the recalling firm | Jul 22, 2024 | 4 x 0.6 | 2.4 |
| Class II recall D-0612-2024, this FEI as the recalling firm | Jun 28, 2024 | 4 x 0.6 | 2.4 |
| Class II recall D-0534-2024, this FEI as the recalling firm | May 13, 2024 | 4 x 0.6 | 2.4 |
| Class II recall D-0532-2024, this FEI as the recalling firm | May 10, 2024 | 4 x 0.6 | 2.4 |
| Class II recall D-0472-2024, this FEI as the recalling firm | Apr 17, 2024 | 4 x 0.6 | 2.4 |
| Class II recall D-0430-2024, this FEI as the recalling firm | Mar 26, 2024 | 4 x 0.6 | 2.4 |
| Class II recall D-0259-2024, this FEI as the recalling firm | Jan 4, 2024 | 4 x 0.6 | 2.4 |
| Class II recall D-0123-2024, this FEI as the recalling firm | Nov 7, 2023 | 4 x 0.6 | 2.4 |
| Class II recall D-0092-2024, this FEI as the recalling firm | Oct 23, 2023 | 4 x 0.6 | 2.4 |
| Class II recall D-0095-2024, this FEI as the recalling firm | Oct 20, 2023 | 4 x 0.6 | 2.4 |
| Class II recall D-1171-2022, this FEI as the recalling firm | Jun 29, 2022 | 4 x 0.6 | 2.4 |
| Class II recall D-1305-2022, this FEI as the recalling firm | Jun 29, 2022 | 4 x 0.6 | 2.4 |
| Class II recall D-0791-2022, this FEI as the recalling firm | Apr 25, 2022 | 4 x 0.6 | 2.4 |
| Class II recall D-0820-2021, this FEI as the recalling firm | Aug 27, 2021 | 4 x 0.25 | 1 |
| Class II recall D-0639-2020, this FEI as the recalling firm | Dec 17, 2019 | 4 x 0.25 | 1 |
| Class II recall D-0156-2020, this FEI as the recalling firm | Oct 22, 2019 | 4 x 0.25 | 1 |
| Class II recall D-1586-2019, this FEI as the recalling firm | Jul 23, 2019 | 4 x 0.25 | 1 |
| Class II recall D-1340-2019, this FEI as the recalling firm | Jun 3, 2019 | 4 x 0.25 | 1 |
| Class II recall D-1120-2019, this FEI as the recalling firm | Mar 25, 2019 | 4 x 0.25 | 1 |
| Class II recall D-0350-2019, this FEI as the recalling firm | Dec 26, 2018 | 4 x 0.25 | 1 |
| Class II recall D-0336-2018, this FEI as the recalling firm | Nov 20, 2017 | 4 x 0.25 | 1 |
| Class II recall D-1229-2014, this FEI as the recalling firm | Mar 18, 2014 | 10 years or older, so it adds no points | 0 |
| Class II recall D-1701-2012, this FEI as the recalling firm | Jul 6, 2012 | 10 years or older, so it adds no points | 0 |
| Class II recall D-1134-2012, this FEI as the recalling firm | Dec 6, 2011 | 10 years or older, so it adds no points | 0 |
| Inspection classified VAI | Jun 29, 2010 | 10 years or older, so it adds no points | 0 |
| Warning letter on FDA's dashboard, which does not show close-outs | Mar 16, 2010 | 10 years or older, so it adds no points | 0 |
| Warning letter on FDA's dashboard, which does not show close-outs | Oct 13, 2009 | 10 years or older, so it adds no points | 0 |
| Warning letter on FDA's dashboard, which does not show close-outs | Mar 30, 2009 | 10 years or older, so it adds no points | 0 |
When each source was last refreshed
| Records | Last refreshed | Source as of | Status |
|---|---|---|---|
| Inspections | Nov 16, 2026 | Newest record Nov 5, 2026 | Current |
| Inspection citations | Nov 16, 2026 | Newest record Nov 5, 2026 | Current |
| Compliance actions (warning letters, injunctions and other action types) | Nov 2, 2026 | Newest record Oct 29, 2026 | Current |
| Warning letter text | Nov 16, 2026 | Newest record Nov 10, 2026 | Current |
| Recalls (Enforcement Report) | Nov 16, 2026 | Newest record Nov 11, 2026 | Current |
| Form 483s and inspection documents | Nov 13, 2026 | Newest record Nov 12, 2026 | Current |
| Import refusals | Nov 15, 2026 | Newest record Nov 5, 2026 | Current |
Reviewing Glenmark Pharmaceuticals Inc., USA as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.
Or check Glenmark Pharmaceuticals Inc., USA yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.
Facility details
- Company
- Glenmark Pharmaceuticals Inc., USA
- Location
- Elmwood Park, NJ (US)
- Source
- inspections